From the above, the synergistic effect of anti-angiogenesis, inhibiting tumor cell proliferation and NKG2D-mediated immunosurveillance resulted in a superior anti-tumor effect in vivo to combination therapy of mAb04 + Docetaxel or Avastin + Docetaxel. The gene discussed is KLRK1; the disease is neoplasm.